Press Releases (-) Any 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2018 September 20, 2018 argenx announces closing of U.S. public offering September 18, 2018 argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering September 16, 2018 argenx announces launch of proposed public offering in the United States September 16, 2018 argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia September 5, 2018 argenx doses first patient in global Phase 3 registration trial of efgartigimod August 28, 2018 argenx receives feedback from Japan’s PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis August 21, 2018 argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody August 9, 2018 argenx to Present at 2018 Wedbush PacGrow Healthcare Conference August 1, 2018 argenx reports second quarter business update and half-year 2018 financial results July 25, 2018 argenx to host conference call & webcast to report second quarter business update July 23, 2018 argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation July 16, 2018 argenx receives milestone payment from strategic collaboration with Shire Pagination First page « First Previous page ‹ Previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page Next › Last page Last »
